Compare TCBK & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCBK | WVE |
|---|---|---|
| Founded | 1975 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.4B |
| IPO Year | 1995 | 2015 |
| Metric | TCBK | WVE |
|---|---|---|
| Price | $47.04 | $12.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | ★ $53.80 | $31.47 |
| AVG Volume (30 Days) | 150.2K | ★ 2.1M |
| Earning Date | 04-23-2026 | 05-29-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | ★ 6.94 | N/A |
| EPS | ★ 3.70 | N/A |
| Revenue | ★ $53,445,000.00 | $3,704,000.00 |
| Revenue This Year | $12.03 | N/A |
| Revenue Next Year | $4.47 | $119.93 |
| P/E Ratio | $12.80 | ★ N/A |
| Revenue Growth | 4.12 | ★ 149.43 |
| 52 Week Low | $35.20 | $5.28 |
| 52 Week High | $53.18 | $21.73 |
| Indicator | TCBK | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 38.45 | 42.11 |
| Support Level | $46.55 | $12.53 |
| Resistance Level | $51.11 | $15.02 |
| Average True Range (ATR) | 1.36 | 0.82 |
| MACD | -0.16 | -0.08 |
| Stochastic Oscillator | 21.22 | 6.46 |
TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.